AHS'I'KAC'I'. Somatomedins/insulin-like growth factors (Sm/lGl;s) are present in blood and in extracts from multiple tissues of the human fetus and induce the proliferation of cultured human fetal cells. ' l o identify the cellular location of immunoreactive Sm/l(;I; in human fetal tissues, we have performed immunocytochemistry in tissues from prostaglandin-induced human fetal abortuses of 12 to 20 wk in gestation. I'vcry tissue studied except the cerebral cortex contains S n i / I G I~ immunoreactive cells. ('ells staining positively include hepatocytes, hepatic hemopoietic cells, columnar epithelia of the pulmonary airways, intestine and kidney tubules, adrenal cortical cells, dermal cells, skeletal and cardiac muscle fibers, and pancreatic islet and acinar cells. Immunostaining was specific for Sm/IGF's, but because of the cross-reactivity of the antibodies it was not possihle to deterniine whether the immunoreactivitj, represented Sm-C/IC;I; I, IGI; 11, or both. 1,iver contained the greatest proportion of immunoreactive cells, while the thymus and spleen had only a few immunostained cells. With the possible exception of dermal and some adrenal cortical cells, the immunoreactive cells do not appear to be the primary sites of Sm/IGI; synthesis, because parallel in situ hybridization hislochemical studies using S m / l G F oligodeoxyribonucleotidc probes show that Sm/I(;F mKN.4s a r e localized predominantly to fibroblasts and mesenchyma1 cells. 'l'hcrefore the immunoreactive cells identified in this study may define sites of action of S m / l G I~s . 
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Srn/IC;Fs (Sm-C/IC;F I and IC;F 11) appear to pla! an important role in the st~niulation of human k t a l growth ( 1 . 2). Both peptides can be detected iri human fctal serurn liom as c:~rl! as 13 wk gestation (1-5). spccitic receptors lor each Sni/l(;I: arc distributed widely in human fetal tissues ( 1. 2). and both are rilitogens for cultured human fetal cells (1. 2. 0. 7). Because Sm/ 1C;Fs appear to be synt1icsi~c.d in rnan! tissucs. the! are thought to act at or near their sites of synthesis as paracrinc or autocr-inc growth factors (8) . Support for this in man conies from the finding that multiple human k t a l tissues of 0 to I0 \vk gestation contain immunoreactive Sm-C'/IC;F I in far gl-eatel-concentrations than can be accounted fbr by blood entrapment (9) . and that rnultiple human fetal tissues of 16 to 20 wk gestation contain m R N A s for both Sm-Cy/IC;F I and IGJ-. 11 (20) .
7'0 identify those cclls \vlicrc Srn/lC;Fs arc locali~cd in the human fetus. we have perfor-mcd immunocytochemistr> on liuman k t a l tissues and have identified cells showing positive immunoreactivity to Sri~/lC;l-s that arc of cpithel~al o r mesodermal origin and. in general. arc diffcrentiateci.
( 'ollclc~/iotl citrcl j)r(y~ciri~tiotl oJ 11.5 SIWS 1'1-ost;lgla~idiri-i 1ic111ccci human fetal abortuses of I? to 20 WE, in gestation wcl-c collected within 30 min of delivery after obtaining per-mission fiom the ethics committees of'the respective institutions. 
I r t i t~~~r t~o c~j~l o~~i i~~t t~i~s i r~~.
I~i i~i i i~~i~c y t o~l i e~i~i s t~.~.
was performed b) the avidin-biotin-peroxidasc technique (10) as ~nodified hy .I-owle c/ (11. ( I I). Briefly. tissue sections were depamtlinizcd in toluene. rehydrated in descending ethanol ser-ies ( 100. 00. and 70%) into PBS and incubated in I hydrogen peroxide in f' BS for I5 min to eliminate endogenous pel-oxidasc acti\.it!. A tier ttir-ee additional PBS rinses. tissue sections ~v e r c incubated in 0.12 mg/ml trypsin (Boehringcr Mannheim Biochemicals, Indianapolis. IN) in PBS for 5 min followed hy thrcc niorc I'RS rinses.
One o f t h c following tlircc primal-> antibodies were used: (a) a Inouse ascitic fluid-derived monoclonal antibod? against Sni-<'/ I G F 1 ( 13. 14) was used at a dilution of I: 1000. (b) a rat antiserum raised against glutaraldehyde corljugates of human I(;J: I1 c-peptide and keyhole limpet hemocyanin was used at a dilution of 1:3000, and (c) a rabbit antiserum against MSA (15) was used at a dilution of 1:1000. Sections were incubated with the antibodies in humidified chambers for 48 h at 4" C. Although the monoclonal antibody raised against SM-C/IGF I was originally reported to have only 5% cross-reactivity with IGF 11 (13, 14) , subsequent studies with different preparations of purified IGF I1 indicate that cross-reactivity is approximately 50%. Cross-reactivity studies of the antiserum to MSA also indicates that it recognizes both human IGF I1 and Sm-C/lGF I (1 5). Immunocytochemistry with rabbit antisera that are highly specific for human SM-c/IGF I in radioimmunoassay (16) resulted in a negative immunostaining. Therefore. these antisera were not used in the study.
Following incubation in primary antibody, the tissue sections were rinsed in PBS, then incubated in appropriate biotinylated second antibody (Vector Laboratories, Burlingame, CA; 1:500 dilution in PBS containing 0.1 % BSA) at room temperature for 2 h. Following additional PBS rinses, tissue sections were incubated in avidin-biotin-peroxidase complex (ABC, Vector Laboratories, Burlingame CA) at room temperature for 2 h, then rinsed again in PBS. The antibody bound peroxidase was visualized by reacting with 0.075% diaminobenzidine (Aldrich Chemical Inc., Milwaukee, WI) in Tris-HCI buffer. pH 7.6, containing 0.002% (v/v) hydrogen peroxide. Tissue sections were then counterstained with 0.05% toluidine blue, dehydrated in ascendingethanol series and xylene, and mounted with coverslips using Pcrmount (Fisher Scientific, Springfield, NJ).
Immunos~)ec~fificity studies. Several experiments were performed to verify that the antibodies used recognized Sm/IGFs specifically. There was an absence of immunostaining when preimmune or nonimmune rat or rabbit sera or nonimmune mouse ascitic fluid were substituted for the primary antibodies. Immunostaining also was not observed when antisera or immune ascitic fluid were immunoabsorbed with 1 to 10 pM of partially purified preparations of either Sm-C/IGF I and IGF I1 (1 7) prior to imrnunostaining. Immunostaining was not altered, however, when antisera or immune ascitic fluid were incubated with 1 to 10 /.LM concentrations of insulin, epidermal growth factor, platelet-derived growth factor and nerve growth factor. Because the antibodies were known to cross-react with both Sm/IGFs, immunoblot studies were performed with pure Sm-C/lGF I and IGF I1 immobilized on nitrocellulose paper (18) to determine if cross-reactivity was significant under conditions similar to those used in immunocytochemistry. At the dilutions used for immunocytochemistry, each antibody gave similar intensity of immunostaining against both peptides. Therefore, while the antibodies identified Sm/IGFs specifically, none was capable of distinguishing between Sm-C/IGF I and IGF 11.
RESULTS
Identical patterns of immunostaining were observed with each antibody in every tissue studied. Immunostained cells of at least one type were seen in all the tissues except the cerebral cortex. The proportion of immunostained cells varied among the tissues studied; the greatest proportion was observed in the liver and adrenal gland and the least in spleen and thymus. Although considerable variation in the intensity of immunostaining was observed among different cell types within the same tissue, the intensity of staining was not pronounced, suggesting that the abundance of Srn/IGFs within the immunopositive cells was not high.
Liver. Moderate staining was observed in about 70% of the hepatocytes (Fig. 1 A and B) . The stained and unstained hepatocytes had the same morphology, and the reason for the difference in immunoreactivity is not known. Fetal liver also contained intensely immunostained small, round nucleated hemopoietic cells with deeply basophilic nuclei. These cells, the identity of which is unclear, were observed in groups in the walls and within the lumina of the hepatic blood vessels. Similar intensely immunoreactive cells also were observed in other tissues. The mature RBCs within the blood vessels and sinusoids were unstained.
Lung. Moderate immunostaining was observed in the columnar epithelium of the primitive airways and lung fluid within the airways (Fig. ID) . The columnar epithelium of both large and small bronchioles were stained, but the intensity of staining varied among the bronchioles. No immunostaining was observed in the pleural lining and the connective tissue of the lung parenchyma.
Kidne.y. Moderate immunostaining was seen in the lining columnar epithelium of the proximal and distal convoluted tubules, and weak staining was observed in the collecting ducts (Fig. 1 F) . No immunostaining was observed in the capsule, tubules of the nephrogenic zone, loops of Henle, connective tissue parenchyma, or glomeruli.
Adrenal. About 60% of the parenchymal cells in the mature adrenal cortex were immunostained, but the fetal zone of the cortex, and the medulla contained no immunoreactive cells (Fig.  I H) .
Pancreas. In 12-to 15-wk fetuses (when the islet cells have not
yet organized), positive immunostaining was observed in the epithelial cells, the presumptive progenitor cells of the exocrine, or endocrine pancreas. In the older fetuses, staining predominated in the islets and was minimal in the exocrine pancreas.
Stomach and small inte.~tinc~. Throughout the gastrointestinal tract, only the epithelial cells of the mucosa showed positive staining (Fig. 1 G) . The columnar cells that lined the villi of the intestine stained more intensely than cells lining the crypts.
Thymus and .spleen. Groups of immunostained cells having
the morphology of immature henlopoietic precursors were observed in the corpuscles and interlobular septa of the thymus and were distributed widely in the parenchyma of the spleen. Most lymphoid cells in the thymic lobules and splenic corpuscles showed no immunostaining.
Skeletal and cardiac muscle. Moderate immunostaining was observed in the fibers of both skeletal (Fig. 1E ) and cardiac muscles, but none was seen in the fibrous sheaths and septa.
Skin. Skin from the anterior abdominal wall showed minimal immunostaining in the stratum granulosum of the epidermis and moderate staining of the deep layers of the dermis (Fig. 1 I) .
No immunostaining was observed in the adnexae of the skin, including hair follicles and sweat glands.
DISCUSSION
Using immunocytochemistry, we have shown that multiple tissues from 12-to 20-wk human fetuses contain cells with Sm/ IGF immunoreactivity. Because the antibodies used in this study recognize both Sm-C/IGF I and IGF 11, identification of specific Sm/IGFs was precluded. Negative immunostaining with an antiserum which is highly specific for Sm-C/IGF I in radioimmunoassay (l5), however, suggests that the immunoreactivity may be attributed predominantly to IGF 11. Both SM-C/IGF I and IGF I1 peptides are probably present in multiple fetal tissues, however, because (a) immunoassayable Sm-C/IGF I is readily detected with a highly specific antibody in extracts of many tissues obtained from human fetuses during the first half of pregnancy (9) Bennington et ul. (18) have reported the localization of Sm-C/IGF 1 in human fetal and adult tissues by an immunoperoxidase technique using a rabbit antiserum to human Sm-C/IGF I. Although a detailed description is lacking, the distribution of Sm-C/IGF I immunoreactive cells appears to be similar to that in our study. Similarly, Andersson et al. (19) recently reported identification of Sm-C/IGF I immunoreactive cells in several tissues from adult rats. Although their antibodies differ in specificity from ours, and the species and ages of the animals studied are also different, the findings in the two studies are similar. One interpretation of our findings and those of others is that immunostaining identifies Sm/IGF synthesizing cells that are dispersed widely in many tissues. We believe that such a conclusion may be erroneous, because immunocytochemical techniques only identify the cellular location of peptides possessing specific antigenic determinants; such techniques do not indicate whether an immunostained cell is a site of synthesis of the antigen or whether it has accumulated the antigen from another source. Using in situ hybridization histochemistry with specific oligodeoxyribonucleotide probes for mRNAs encoding Sm-C/IGF I and IGF 11, we have observed that Sm/IGF transcripts in human fetal tissues are localized predominantly in fibroblastic and mesenchymal cells (20) . In general, these Sm/IGF mRNAs are localized to connective tissue elements such as organ capsules and septa. Furthermore, most of the immunopositive cells observed in the present study did not possess Sm/IGF mRNAs in significant abundance to be identified by in situ hybridization. While this lack of concordance among cells identified by the two techniques suggests that most of the immunostained cells do not synthesize Sm/IGFs, it is possible that the mRNAs of some fetal cells are unstable, are not translated, or result in production of a peptide form that is not recognized by the antibodies used. On the other hand, immunostained cell may have sequestered Sm/ IGF from other sources by cell surface binding with subsequent internalization (2 1) and sequestration in endoplasmic reticulum, as has been shown for vascular endothelium (22) . Moreover, the immunoreactive cells may be sites of degradation of the peptides. Regardless of the mechanisms involved, the immunolocalization of Sm/IGF to specific cells in vivo is likely to have physiologic significance.
The observation that fibroblasts, which are rich in Sm/IGF mRNA and are capable of Sm/IGF synthesis in culture (23) (24) (25) , usually exhibit no immunostaining suggests that these cells have little capacity to store Sm/IGFs. A paucity of intracellular storage is supported by the delay of 4 to 8 h in a rise of Sm-C/IGF I in t i s s u c s a n d p l a s m a f o l l o w i n g t h c injection of G H i n t o h y p o p h ysectomized rats (8) and a similar delay when G H is administered in man (26, 27) . In contrast, cultured human fetal hepatocytes appear to store Sm/IGFs since they immunostain for these peptides (28). This Sm/IGF is released from both rat and human isolated fetal hepatocytes under hormonal control (28, 29). It is not yet known whether the Sm/IGF present and released is due to sequestration or de novo synthesis.
In most of the tissues we examined, the connective tissue cells that possess Sm/IGF mRNAs are near the cells that exhibit Sm/ IGF immunoreactivity. This juxtaposition of cells that synthesize Sm/IGFs with those that may respond to Sm/IGFs supports the paracnne hypothesis of action of these peptides. The dermis (and possibly adrenal cortex) may be an exception, because in this tissue immunostaining and in situ hybridization occur in the same cells. If this is the case, an autocrine mechanism of growth control could be operative (30, 3 1). The observation that Sm/ IGF immunoreactivity is prominent in differentiated cells support the concept that these peptides are important mediators of differentiated cell functions (30-33), as well as proliferation.
The results of the present study can be interpreted in a number of ways. We believe, however, that these immunolocalization studies indicate sites where Sm/IGFs are accumulated and/or act given the evidence from in situ hybridization histochemistry that most of the immunostained cells are not the major sites of Sm/IGF gene expression. Large et al. (34) found markedly different abundances of NGF and its mRNA in different brain regions. Although these alterations in relative abundance may be explained by neuronal retrograde transport of NGF through axons, it seems possible that other mechanisms, such as those we have postulated, may be responsible for the discrepancies in Sm/IGF immunolocalization and in situ hybridization histochemistry that we have observed.
